Synox leads are designed for use with implantable pulse generators that require pacing leads with a bipolar 3.2 mm IS-1 connector configuration; they may be used with single or dual chamber pacing systems. The leads are designed for use in patients for whom single or dual chamber pulse generator therapy is medically indicated. This indication follows that recommended in the Class I definition of the ACC/AHA Task Force Report, entitled "Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmic Devices" (JACC, Vol. 18, No. 1, July 1991:1 - 13).

Device Description

Synox xx/15-BP leads are bipolar, passive fixation endocardial leads that feature three for fixation in the heart's trabeculae. The tip electrode is made of a titanium base material with a surface treatment of fractal iridium and a surface area of 1.3 mm². The ring electrode is made of a platinum/iridium base material with a surface treatment of fractal iridium and a surface area of 34 mm². The lead conductor is quadrifilar MP35N wire in a coaxial configuration, insulated with sillcone rubber tubing. All Synox leads utilize a 3.2 mm IS-1 connector.

AI/ML Overview

The provided 510(k) notification for the BIOTRONIK Synox Passive Fixation Endocardial Lead describes a medical device, not an AI/ML powered device. As such, it does not involve the typical "acceptance criteria" and "study that proves the device meets the acceptance criteria" in the context of AI/ML performance metrics (like accuracy, sensitivity, specificity).

Instead, the submission focuses on demonstrating substantial equivalence to a predicate device. This is a regulatory pathway where the new device is compared to a legally marketed device (the predicate) in terms of intended use, technological characteristics, and safety and effectiveness.

Therefore, many of the requested elements regarding sample sizes for training/test sets, expert adjudication, MRMC studies, standalone performance, and ground truth establishment are not applicable.

Here's an attempt to answer the questions based on the provided document, interpreting "acceptance criteria" in the context of substantial equivalence:

1. A table of acceptance criteria and the reported device performance

In the context of a 510(k) for substantial equivalence, the "acceptance criteria" are implicitly met if the new device is shown to be as safe and effective as the predicate device. The document states the modification is a reduction in electrode spacing and a change in silicone insulation. The performance is implied to be equivalent to the predicate device because of the minor nature of the changes and the direct comparison to existing approved designs.

Acceptance Criteria (Implied for Substantial Equivalence)	Reported Device Performance
Intended Use: Identical to predicate device.	Confirmed. Indications for Use are consistent with predicate.
Technological Characteristics:
- Bipolar, passive fixation endocardial lead.	Confirmed.
- Three tines for fixation.	Confirmed.
- Tip electrode material and surface area.	Confirmed (titanium base, fractal iridium, 1.3 mm²).
- Ring electrode material and surface area.	Confirmed (platinum/iridium base, fractal iridium, 34 mm²).
- Lead conductor type and insulation.	Confirmed (quadrifilar MP35N wire, silicone rubber).
- IS-1 connector.	Confirmed (3.2 mm IS-1).
- Electrode spacing (New vs. Predicate)	New: 15 mm. Predicate: 31 mm (straight), 15 mm ("J" shaped). The new 15mm spacing is deemed identical to the "J" shaped Synox leads, which are also predicates.
- Silicone insulation design (New vs. Predicate)	Modified from tapered to consistent thickness due to reduced spacing. This is a design change, but not presented as impacting safety/effectiveness.
Safety and Effectiveness: No new questions of safety or effectiveness are raised compared to the predicate device.	Implied by the FDA's clearance letter ("We have determined the device is substantially equivalent...").

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Not applicable. This is not an AI/ML performance study. The 510(k) submission relies on demonstrating substantial equivalence to a predicate device and engineering design changes. No specific "test set" of patient data or clinical study data is detailed in the provided summary for performance evaluation.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

Not applicable. No "ground truth" establishment by experts in the context of AI/ML validation is described. The "ground truth" for substantial equivalence is the predicate device's established safety and effectiveness.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. There is no described "test set" requiring adjudication.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This device is not an AI-assisted diagnostic tool.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This is a hardware medical device (pacemaker lead), not an algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Not applicable in the AI/ML sense. The "ground truth" equivalent in a 510(k) is the established safety and effectiveness of the predicate device(s). The FDA's clearance signifies that the new device is substantially equivalent to these legally marketed predicates.

8. The sample size for the training set

Not applicable. No AI/ML model training is involved.

9. How the ground truth for the training set was established

Not applicable. No AI/ML model training is involved.

Summary of the Study that Proves the Device Meets Acceptance Criteria (Substantial Equivalence):

The study described is a regulatory submission based on substantial equivalence. The manufacturer (BIOTRONIK, Inc.) demonstrated that the Synox 53/15-BP and 60/15-BP leads are substantially equivalent to their own currently marketed and FDA-cleared predicate devices (Synox leads approved under K980869).

The "proof" for substantial equivalence was established by:

Identifying Predicate Devices: BIOTRONIK's Synox passive fixation endocardial leads (straight and "J" configurations) cleared under K980869.
Comparing Intended Use: Showing the new leads share the identical intended use with the predicate devices.
Comparing Technological Characteristics: Highlighting that the new device is a modified version of existing Synox leads. The primary modification is a reduction in the distance between ring and tip electrodes from 31 mm to 15 mm and a corresponding change in the silicone insulation. Crucially, the 15 mm spacing is identical to that of other "J" shaped Synox leads already cleared as predicates. Other characteristics (materials, surface treatment, conductor, connector) are stated to be the same as the predicate.
Demonstrating No New Questions of Safety/Effectiveness: By showing the changes are minor and by comparing them to already cleared designs (specifically, the 15mm spacing already exists in predicate "J" leads), the submission implicitly argued that no new safety or effectiveness concerns were raised that would differentiate it from the predicate.

The FDA's clearance letter ("We have reviewed your Section 510(k) notification... and we have determined the device is substantially equivalent...") serves as the official "proof" that the device meets the regulatory acceptance criteria for market entry via the 510(k) pathway.

Summary

{0}------------------------------------------------

BIOTRONIK, Inc., Synox Passive Fixation Endocardial Lead, 510(k)

Synox Passive Fixation Endocardial Lead 510(k) Notification

510(K) SUMMARY 1.

Name and Address of Sponsor:	BIOTRONIK, Inc.6024 Jean RoadLake Oswego, OR 97035
Establishment Registration Number:	1028232
Device Name:	Proprietary Names: Synox LeadsClassification: Class III (21 CFR 870.3680(b))Classification Name: Cardiovascular PermanentPacemaker ElectrodeProduct Code: DTB
Date Prepared:	April 2, 1999

General Description and Predicate Devices:

The Synox 53/15-BP and 60/15-BP leads introduced in this 510(k) notification are modified versions of BIOTRONIK's currently marketed straight Synox leads (SX 53-BP and SX 60-BP) approved September 10, 1998 under 510(k) #K980869. The modification is a reduction of the distance between the ring and tip electrodes from 31 mm to 15 mm. Because of this change, the silicone insulation between the tip and ring electrodes was shortened and the prior tapered design was changed to one with a consistent thickness. The new 15 mm spacing distance between the ring and tip electrodes is identical to the electrode spacing of the "J" shaped Synox leads (SX 45-JBP and SX 53-JBP) also approved September 10, 1998 under 510(k) #K980869. The SX xx/15-BP straight leads with 15 mm spacing will not replace the existing straight leads, but will be distributed in conjunction with the currently marketed Synox leads.

The predicate devices are BIOTRONIK'S Synox passive fixation endocardial leads (straight and "U" configurations) cleared for commercial distribution on September 10, 1998 under 510(k) #K980869.

Indications for Use:

Name and Address of Manufacturing Site:

BIOTRONIK GmbH & Co. (reg. no. 7010992) Woermannkehre 1, 12359 Berlin, Germany 011-49-30-689-05-304

Contact Person(s) and Phone Number: Jon Brumbaugh Regulatory Affairs Manager Phone (888) 345-0374 Fax (503) 635-9936

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized graphic of an eagle or bird with three curved lines representing its wings or feathers. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the graphic.

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL - 1 1999

Mr. Jon Brumbaugh Manager, Regulatory Affairs BIOTRONIK, Inc. 6024 Jean Road Lake Oswego, OR 97035

Re : K991169 Trade Name: Synox SX 53/15-BP and SX 60/15-BP Endocardial Pacing Leads Regulatory Class: III Product Code: DTB Dated: April 2, 1999 Received: April 7, 1999

Dear Mr. Brumbaugh:

We have reviewed your Section 510 (k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. You may, therefore, market the device, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act). The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, and labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to A substantially equivalent determination assumes compliance with 895. the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, FDA will verify such assumptions. Failure to comply with the GMP requlation may result in requlatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Reqister. Please note: this response to your premarket notification submission does not affect any obliqation you might have under section 531 through 542 of the Act for devices

{2}------------------------------------------------

Page 2 - Mr. Jon Brumbaugh

under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.

On August 16, 1993 the Final Rule for Device Tracking was published in the Federal Register, pages 43442-43455 (copy enclosed). Be advised that under Section 519(e) of the Act as amended by the Safe Medical Devices Act of 1990, FDA has identified the above device as a device which requires tracking. Because the device is subject to tracking, you are required to adopt a method of tracking that follows the devices through the distribution chain and then identifies and follows the patients who receive them. The specific requirements of the regulation are found in 21 CFR 821 as described in the August 16, 1993 Federal Reqister beginning on page 43447.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) Additionally, for questions on the promotion and advertising 594-4586. of your device, please contact the Office of Compliance at (301) 594-4639. Also, please not the regulation entitled, " Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act, may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Quitymthater

Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

{3}------------------------------------------------

INDICATIONS FOR USE 2.

Synox leads are designed for use with implantable pulse generators that require pacing hads with a Synox leads are designed for use with implanable pares with single or dual chamber pacing bigolar 3.2 min 10-1 connector ochingation, they may whom single or dual chamber pulse generator Systems. The leads are dolly indication follows that recommended in the Class I definition of the theraly is including indicated. This includines for Implantation of Cardiac Pacemakers and Antiarrhythmic Devices" (JACC, Vol. 18, No. 1, July 1991:1 - 13).

C. Witzman for Callahan

(Division Sign-Off) Division of Cardiovascular rological Devic 510(k) Numb

Image /page/3/Picture/6 description: The image shows a handwritten note with the name "Mike" at the top left. Below "Mike", the words "prescription-device" are written inside a roughly drawn circle. At the bottom of the image, there is a signature that appears to read "Chi".

Regulation Number and Section

§ 870.3680 Cardiovascular permanent or temporary pacemaker electrode.

(a)
Temporary pacemaker electrode —(1)Identification. A temporary pacemaker electrode is a device consisting of flexible insulated electrical conductors with one end connected to anexternal pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator.(2)
Classification. Class II (performance standards).(b)
Permanent pacemaker electrode —(1)Identification. A permanent pacemaker electrode is a device consisting of flexible insulated electrical conductors with one end connected to an implantable pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator.(2)
Classification. Class III (premarket approval).(c)
Date PMA or notice of completion of PDP is required. A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before October 4, 2012, for any permanent pacemaker electrode device that was in commercial distribution before May 28, 1976, or that has, on or before October 4, 2012, been found to be substantially equivalent to any permanent pacemaker electrode device that was in commercial distribution before May 28, 1976. Any other pacemaker repair or replacement material device shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.